


COST-COMPARISON OF SECUKINUMAB AND USTEKINUMAB FOR TREATMENT OF PSORIASIS

Suarez Gonzalez, M., Gomez Melini, E., Diaz Ruiz P., Ramos Santana E., Plasencia García, I., Hernandez Rojas S., Ocaña Gomez MA., Merino Alonso J.

Pharmacy Service Hospital Universitario Ntra. Sra. de Candelaria, Tenerife, SPAIN



23rd Congress of the EAHP (Gothenburg 2018)



BACKGROUND

- **Secukinumab** is a monoclonal antibody designed to recognise and attach to a messenger molecule in the immune system called interleukin 17A whereas **Ustekinumab** is also a monoclonal antibody attaches to two cytokines called interleukin 12 and interleukin 23.
- All these cytokines are involved in the inflammation and other immune system processes that cause Psoriasis. By blocking their activity, both Secukinumab and Ustekinumab reduce the activity of the immune system and the symptoms of the disease.

PURPOSE


- To estimate the cost-comparison of Secukinumab and Ustekinumab following inadequate response to biologic drugs in patients with moderate to severe plaque psoriasis.

MATERIAL AND METHODS

- Cost evaluation of Psoriasis patients treated with Secukinumab or Ustekinumab following inadequate response to Adalimumab or Etanercept in a third-tier hospital for 2 years (2015-2017).
- The increase or decrease of costs were analyzed when we change from one biological therapy to another.
- We also studied how many naive patients started with Secukinumab or Ustekinumab as first line of treatment.
- The information has been obtained from the Electronic Clinical History (SELENE®) and the Pharmacy Service Managing Software (FARMATOOLS®).


RESULTS

Biological therapies



- Etanercept (58 patients)
- Adalimumab (43 patients)
- Ustekinumab (30 patients)
- Secukinumab (13 patients)

Naive patients



- Ustekinumab (12 patients)
- Secukinumab (2 patients)

Nº patients	Previous biologic	New biologic	Cost (€/año)
7	Etanercept	Secukinumab	11356,8
1	Adalimumab	Secukinumab	2231,6
3	Ustekinumab	Secukinumab	6761,7
9	Etanercept	Ustekinumab	-5683,5
8	Adalimumab	Ustekinumab	-178,4
1	Secukinumab	Ustekinumab	-2253,9
Cost increased			12234,3

CONCLUSION

- Ustekinumab supposes the best cost for Psoriasis in this study.
- Furthermore, its administration is more comfortable for patients due to Ustekinumab is given every 12 weeks versus Secukinumab is given two injections every 4 weeks.
- Ustekinumab could also represent a treatment opportunity for patients non-adherence.